Shafa Amir, Rajabi Fatemeh, Golkar Kimia, Habibzadeh Mohammad Reza
Department of Anesthesiology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Department of Psychiatry, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Iran J Psychiatry. 2022 Jul;17(3):304-311. doi: 10.18502/ijps.v17i3.9730.
One of the most common complications in general anesthesia is the Emergence delirium (ED). Many agents have been studied for prevention of ED, among which propofol has been successfully used. However, there is no information about the optimal dosage of this agent considering the ultimate outcome and the adverse effects; therefore, aimed to assess in this study. 70 children undergoing general anesthesia using propofol, fentanyl, and atracurium were assessed. Participants were allocated randomly to treatment with either propofol 1 mg/kg (n = 35) or 0.5 mg/kg (n = 35) by the end of the anesthesia. The Pediatric Anesthesia Emergence Delirium (PAED) Scale, Face, Legs, Activity, Cry, Consolability (FLACC) scale, and the University of Michigan Sedation Scale (UMSS) were assessed by 10-minute intervals. Post-anesthesia care unit (PACU) stay and adverse effects were registered and compared as well. Duration of PACU stay (P < 0.001), PAED (P = 0.001), and UMSS (P = 0.003) were remarkably lower among low-dose propofol-treated children in the assessment at the 30th minute, while there were no significant differences in FLACC scores between the groups (P > 0.05). Apnea was found in a patient (2.85%) treated with high-dose propofol and decreased oxygen saturation was demonstrated in 5 (14.28%) and 2 (5.71%) participants in high- versus low-dose propofol. None of the patients experienced postoperative nausea and vomiting. Based on the current study, propofol 0.5 mg/kg by the end of anesthesia could efficiently prevent ED incidence and reduce time of PACU stay and adverse effects compared to a high dose of 1 mg/kg.
全身麻醉最常见的并发症之一是苏醒期谵妄(ED)。已经对多种药物进行了预防ED的研究,其中丙泊酚已被成功应用。然而,考虑到最终结果和不良反应,关于该药物的最佳剂量尚无相关信息;因此,本研究旨在对此进行评估。对70例接受丙泊酚、芬太尼和阿曲库铵全身麻醉的儿童进行了评估。在麻醉结束时,参与者被随机分为丙泊酚1mg/kg组(n = 35)或0.5mg/kg组(n = 35)进行治疗。每隔10分钟评估一次小儿麻醉苏醒期谵妄(PAED)量表、面部、腿部、活动、哭闹、安抚性(FLACC)量表以及密歇根大学镇静量表(UMSS)。同时记录并比较麻醉后监护病房(PACU)的停留时间和不良反应。在第30分钟的评估中,低剂量丙泊酚治疗的儿童在PACU停留时间(P < 0.001)、PAED(P = 0.001)和UMSS(P = 0.003)方面显著更低,而两组之间的FLACC评分无显著差异(P > 0.05)。高剂量丙泊酚治疗的一名患者出现呼吸暂停(2.85%),高剂量与低剂量丙泊酚组分别有5名(14.28%)和2名(5.71%)参与者出现氧饱和度下降。所有患者均未出现术后恶心和呕吐。基于本研究,与高剂量1mg/kg相比,麻醉结束时使用0.5mg/kg丙泊酚可有效预防ED的发生,并减少PACU停留时间和不良反应。